Success Questioned in Much-Hyped Indian Antimissile Test

Global Security Newswire Staff
Global Security Newswire Staff
May 15, 2014, 9:25 a.m.

In­dia’s much-hyped April mis­sile in­ter­cept­or test may not have been the great suc­cess the mil­it­ary ini­tially claimed, the New In­di­an Ex­press re­ports.

Im­me­di­ately after the April 27 test, an uniden­ti­fied In­di­an De­fense Re­search and De­vel­op­ment Or­gan­iz­a­tion seni­or sci­ent­ist was quoted by the In­di­an States­man as call­ing the maid­en test of the Prithvi De­fense Vehicle “a com­plete suc­cess as it met all of its ob­ject­ives without any flaws.”

But the Ex­press news­pa­per re­por­ted on Thursday that the in­ter­cept­or nev­er struck its tar­get. The Prithvi vehicle passed the tar­get, and its war­head failed to det­on­ate, ac­cord­ing to sources at the Wheel­er Is­land In­teg­rated Test Range

“The in­ter­cept­or did not dir­ectly hit the tar­get mis­sile,” an an­onym­ous of­fi­cial said. “So it can­not be claimed that a hit-to-kill took place dur­ing the mis­sion.”

Ad­di­tion­ally, the Prithvi in­ter­cept­or did not reach its in­ten­ded height of a min­im­um of 75 miles.

“The missed dis­tance between the in­ter­cept­or and the tar­get was more than what was ex­pec­ted,” the of­fi­cial said. “But we still can say that the mis­sion was par­tially suc­cess­ful as the in­ter­cept­or could be fired in time. In an auto­mated op­er­a­tion, a radar-based de­tec­tion and track­ing sys­tem suc­cess­fully de­tec­ted and tracked the en­emy bal­list­ic mis­sile.”

DRDO head Avinash Chander is now as­sert­ing there nev­er was a plan for the in­ter­cept­or’s war­head to ex­plode, and that the prin­cip­al pur­pose of the test was to mon­it­or the tra­ject­ory of the mis­sile tar­get.

Mean­while, the In­di­an mil­it­ary is pre­par­ing to con­duct a test as soon as next month of the nuc­le­ar-ready Nirbhay cruise mis­sile, the Times of In­dia re­por­ted. This would be the second tri­al of the weapon, which is said to be cap­able of be­ing launched from air, sea and land.

The maid­en test of the weapon last year ended in fail­ure when the launched mis­sile de­vi­ated from its pro­grammed flight course and had to be re­motely des­troyed. The Nirbhay is re­portedly de­signed to carry nuc­le­ar pay­loads as far as 621 miles and has been com­pared to the U.S. Toma­hawk mis­sile.

What We're Following See More »
Grassley Open to Lame Duck Hearings on Garland
14 hours ago

Senate Judiciary Committee Chairman Chuck Grassley (R-IA) said Monday he'd now be willing to hold a hearing on Supreme Court nominee Merrick Garland in a lame-duck session of Congress. While he said he wouldn't push for it, he said if "Hillary Clinton wins the White House, and a majority of senators convinced him to do so," he would soften his previous opposition.

Monmouth Has Clinton Up Seven
18 hours ago

In a new Monmouth University poll, 46% of likely voters support Clinton and 39% back Trump, with 7% supporting Libertarian Gary Johnson, and 2% backing Jill Stein of the Green Party. That's down from a poll taken right after the Democratic convention, in which Clinton led by 13 points.

Clinton Advisers Talking to Psychologists, Trump Ghostwriter
18 hours ago

“Hillary Clinton’s advisers are talking to Donald J. Trump’s ghostwriter of The Art of the Deal, seeking insights about Mr. Trump’s deepest insecurities as they devise strategies to needle and undermine him in four weeks at the first presidential debate, the most anticipated in a generation. ... Her team is also getting advice from psychology experts to help create a personality profile of Mr. Trump to gauge how he may respond to attacks and deal with a woman as his sole adversary on the debate stage.”

House Committee Investigating Mylan
21 hours ago

The House Committee on Oversight and Government Reform has requested documents from the CEO of Mylan, "the pharmaceutical company under fire after raising the price of EpiPens more than 400 percent since 2007." Meanwhile, top members of the Energy and Commerce Committee are pressing the FDA on the lack of generic competition for EpiPens.